Pharma Exclusives Pressreleases
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
Friday, January 31, 2025Merckknown as MSD outside of the United States and Canada announced today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA recommended the approval of CAPVAXIVE Pneumococcal valent Conjugate Vaccine fo...
Enhertu receives US approval as the first HER2-targeted therapy for HER2-low or HER2-ultralow metastatic breast cancer after progression on prior endocrine treatment
Tuesday, January 28, 2025AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HRpositive HERlow IHC or IHC ISH or HERultralow IHC with membrane staini...
Olink® Reveal Seamlessly Connects Genomics and Proteomics, Empowering Researchers to Uncover the Dynamic Mechanisms Underlying Biology
Monday, January 27, 2025Thermo Fisher Scientific the world leader in serving science today announced the introduction of Olink Reveal setting a new standard for affordable highplex proteomics that enables researchers to identify circulating biomarkers for a range of applica...
FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
Monday, January 27, 2025Merck known as MSD outside of the United States and Canada today announced the US Food and Drug Administration FDA has accepted for priority review a supplemental new drug application sNDA seeking approval of WELIREG belzutifan Mercks oral hypoxiaind...
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
Monday, January 27, 2025Lantern Pharma Incan artificial intelligence AI company dedicated to developing cancer therapies and transforming the cost pace and timeline of oncology drug discovery and development today announced advancements in the application of its RADR AI pla...
AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery
Friday, January 24, 2025AstraZeneca a global pharmaceutical company focused on developing life changing medicines today announced a C million USm investment in Canada creating more than highskilled jobs across all areas of the business
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Friday, January 24, 2025AbbVieand Neomorph Inc today announced a collaboration and optiontolicense agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
Friday, January 24, 2025Moderna Inctoday announced that it has been awarded a tender for the supply of its mRNA COVID vaccine in the European Union EU Norway and North Macedonia Under the resulting agreement participating countries can access Modernas mRNA COVID vaccine fo...
BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
Thursday, January 23, 2025BD a leading global medical technology company and Biosero a developer of laboratory automation solutions to orchestrate scientific discoveries today announced a framework collaboration agreement to enable and facilitate robotic arm integration
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Wednesday, January 22, 2025Shuttle Pharmaceuticals Holdings Inc a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy RT announced today that it has achieved enrollment in the initia...
